搜尋
NewAmsterdam Pharma Company NV
NAMS添加自選
33.890USD
+0.020+0.06%
收盤 06/30, 16:00（美東）報價延遲15分鐘
3.96B總市值
虧損本益比TTM
關鍵數據
34.590今開
34.725最高
1.08M成交量
虧損本益比TTM
虧損本益比動
--股利TTM
0.92%換手率
33.870昨收
33.575最低
27.88M成交額
虧損本益比靜
5.94市淨率
0.00%股息率 TTM
-27.43%ROA
42.00052週最高
0.79量比
-241.60M淨利潤
116.64M總股本
-1.7787每股盈餘TTM
0.16Beta
-29.49%ROE
14.06052週最低
3.40%振幅
100.00%毛利率
3.96B總市值
1.89回報/風險
3.46%風險率
TradingKey NewAmsterdam Pharma Company NV股票評分
單位: USD 更新時間: 2026-06-30操作建議
NewAmsterdam Pharma Company NV當前公司基本面數據相對非常健康，增長潛力很大。當前估值合理，在生物技術與醫療研究行業排名20/387位。機構持股佔比非常高，近一月多位分析師給出公司評級為買入。最高目標價為51.50。中期看，股價處於平穩狀態。近一個月，市場表現較強，技術面和基本面綜合得分較高，較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間，可以做區間波段操作。
NewAmsterdam Pharma Company NV評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
公司輿情
過去24小時
熱度
過冷
過熱
中性
NewAmsterdam Pharma Company NV亮點
亮點風險
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
業績高增長
公司營業收入穩步增長，連續3年增長59.71%
業績增長期
公司處於發展階段，最新年度總收入22.50M美元
利潤高增長
公司淨利潤處於行業前列，最新年度總收入22.50M美元
估值低估
公司最新PE估值-19.05，處於3年歷史低位
機構加倉
最新機構持股128.70M股，環比增加1.86%
分析師目標
基於
16
分析師
買入
評級
51.500
目標均價
+52.05%
漲幅空間
NewAmsterdam Pharma Company NV新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
NewAmsterdam Pharma Company NV簡介
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
公司代碼NAMS
公司NewAmsterdam Pharma Company NV
CEODavidson (Michael Harvey)
網址https://ir.newamsterdampharma.com/
相關品種
-2.50%
-1.79%
-1.22%
-0.57%
-0.73%
-0.56%
+0.44%
-0.86%
+0.01%
-2.42%
-0.58%
-1.64%
-0.76%
-1.77%
+1.01%
0.00%
-1.31%
+1.68%
+0.56%
+0.28%熱門品種
52181.500
-14.800 (-0.03%)
30084.100
-140.500 (-0.47%)
7468.200
-14.200 (-0.19%)
15293.000
-302.000 (-1.94%)
70591.000
-265.000 (-0.37%)
6317.800
-9.200 (-0.14%)
68.498
-1.423 (-2.04%)
289.360
+7.620 (+2.70%)
200.090
+5.120 (+2.63%)
3980.510
-26.770 (-0.67%)
常見問題
NewAmsterdam Pharma Company NV(NAMS)的當前股價是多少？
NewAmsterdam Pharma Company NV(NAMS)的當前股價是 33.89。
NewAmsterdam Pharma Company NV 的股票代碼是什麼？
NewAmsterdam Pharma Company NV的股票代碼是NAMS。
NewAmsterdam Pharma Company NV股票的52週最高點是多少？
NewAmsterdam Pharma Company NV股票的52週最高點是42.00。
NewAmsterdam Pharma Company NV股票的52週最低點是多少？
NewAmsterdam Pharma Company NV股票的52週最低點是14.06。
NewAmsterdam Pharma Company NV的市值是多少？
NewAmsterdam Pharma Company NV的市值是3.95B。
現在NewAmsterdam Pharma Company NV(NAMS)的股票是買入、持有還是賣出？
根據分析師評級，NewAmsterdam Pharma Company NV(NAMS)的總體評級為買入，目標價格為51.50。
NewAmsterdam Pharma Company NV(NAMS)股票的每股收益（EPS TTM）是多少
NewAmsterdam Pharma Company NV(NAMS)股票的每股收益（EPS TTM）是-1.72。